Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp (NQ: LEXX )

0.7602 +0.0002 (+0.03%)
Streaming Delayed Price Updated: 3:26 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Lexaria Bioscience Corp. (NASDAQ: LEXX) Finalizes DehydraTECH(TM)-CBD Batch Manufacturing for IND Filing This Summer and FDA Phase 1b Trial Commencement in October 2023
Via Investor Brand Network
Exposures Product Safety
Lexaria Bioscience Corp. (NASDAQ: LEXX) Shareholders Approve Board Appointments Amid Push for Diversity; Vote to Endorse 6 Agenda Items in 2023 Annual Shareholder Meeting
Via Investor Brand Network
Exposures COVID-19
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Findings from DehydraTECH-CBD Hypertension Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria's Formulated Cannabidiol Showed Reduction In Pro-Inflammatory Biomarkers Associated with Heart Diseases
 
Via Benzinga
Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery
Via ACCESSWIRE
Lexaria Announces 2023 Annual Meeting Results
Via ACCESSWIRE
Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes $2 Million Public Offering Consisting of Common Shares and Accompanying Warrants
Via Investor Brand Network
Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Human Oral Nicotine Study, Hopes to Facilitate More Satisfying Experience with DehydraTECH(TM)-Processed Oral Nicotine
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Human Oral Nicotine Study, Hopes to Facilitate More Satisfying Experience with DehydraTECH(TM)-Processed Oral Nicotine
Via CannabisNewsWire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Pivotal Milestones Concerning DehydraTECH(TM) Technology, Including IND Application Plans
Via Investor Brand Network
TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Demonstrates Significant Enhancement in Oral Estradiol Delivery
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Study Shows Significant Improvements In Peak Bloodstream Estradiol Delivery Using Lexaria's DehydraTECH
Lexaria Bioscience Corp (NASDAQ: LEXX) announces that its animal study HOR-A22-1 has been completed, showing significant enhancement in the oral delivery of the  
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off FDA IND Filing Process with Granted CRO Contract to California-Based InClin, Inc.
Via Investor Brand Network
Exposures Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures $2M in Public Offering
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures $2M in Public Offering
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of cGMP Manufacturing for Upcoming Clinical Trial
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of cGMP Manufacturing for Upcoming Clinical Trial
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Lexaria Bioscience Announces Closing of $2.0 Million Public Offering
Via ACCESSWIRE
cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of 2023 Annual Meeting
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Results of 2023 Annual Meeting
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
Why Is Nikola (NKLA) Stock Down Today?
Nikola (NKLA) stock is taking a beating on Tuesday after the company announced bad news alongside its latest earnings report. 
Via InvestorPlace
Novavax Layoffs 2023: What to Know About the Latest NVAX Job Cuts
Novavax (NVAX) layoffs are on the way as the vaccine maker revealed plans to cut a large portion of its workforce on Tuesday! 
Via InvestorPlace
Why Is Lexaria Bioscience (LEXX) Stock Down 27% Today?
Lexaria Bioscience (LEXX) stock is falling on Tuesday after the company revealed details about its public share offering. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.